CooperVision’s MiSight one day contact lens for childhood myopia has been approved by the US Food and Drug Administration (FDA).
The MiSight lens, clinically proven to slow the progression of myopia when initially prescribed for children aged eight to 12, will be the only product of its kind available in the US.
“We can’t overstate the importance and potential impact of this landmark decision on children’s vision, especially considering the rise in myopia’s severity and prevalence in the US and worldwide. Eyecare professionals who embrace this breakthrough approach will improve the quality of life and eye health for so many children,” said CooperVision ‘s president Daniel McBride.
MiSight daily lens will be launched in the US as part of CooperVision’s myopia management initiative in March 2020.